Thierry Poynard - Publications#

1,141 Publications (WoS), h-index= 110 (WoS), 115 (Scopus), 137 (Google-Scholar), including 3 with more than 3000 citations (Google Scholar).

Eight "old" publications with high citations and recognitions:

1. Bedossa P and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996

2. Poynard T et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997.

3. Poynard T et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon. Lancet 1998.

4. Imbert-Bismut F (...) Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001.

5. Poynard T et al. Viral hepatitis C. Lancet 2003.

6. Lai, CL, (...) Poynard T. Viral hepatitis B. Lancet 2003

7. Poynard T, et al. A comparison of 3 Interferon Alfa-2b regimens for the long-term treatment of chronic Non-A, Non-B-Hepatitis. New England Journal of Medicine 1995

8. Poynard T et al. Beta-adrenergic antagonist drugs in the prevention of gastrointestinal-bleeding in patients with cirrhosis and esophageal-varices - an analysis of data and prognostic factors in 589 patients from 4 randomized clinical-trials. New England Journal of Medicine 1991.

Two recent publications:

9. Poynard T et al. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. APT 2011.

10. Poynard T et al. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. J Hep Reports 2021.

Thierry Poynard founded BioPredictive company in 2002, invented 14 patented or pending tests: FibroTest, ActiTest, SteatoTest, AshTest, NashTest, GenoFibroTest, ElastoFibroTest, ST2, NT2, DILI-ActiTest, NashFibroTest, LiverCancerRisk-1, LiverCancerRisk-2, A1HPV6. All these patents belong to public organizations Assistance Publique Hôpitaux de Paris-Sorbonne University.